Bayer to Build Cell Therapy Pipeline with BlueRock Therapeutics Acquisition

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 8 (Table of Contents)

Published: 16 Aug-2019

DOI: 10.3833/pdr.v2019.i8.2451     ISSN: 1756-7874

Section: Research & Development



Less than three years after forming BlueRock Therapeutics with Versant Ventures, Bayer has now moved to fully acquire BlueRock which focuses on engineered cell therapies in the areas of neurology, cardiology and immunology...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details